Results 91 to 100 of about 4,080,009 (401)
Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia +20 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age‐ and BMI‐adjusted) with absolute concentrations for the prediction of response to disease‐modifying therapy.
Maximilian Einsiedler +43 more
wiley +1 more source
Cytokine, Chemokine, and Neurofilament Light Chain Signatures in LGI1 Autoimmune Encephalitis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objectives To investigate the value of cytokine, chemokine, and neurofilament light chain (NfL) concentrations in predicting relapse risk, chronic epilepsy, and functional impairment in LGI1 autoimmune encephalitis (AE). Methods Cytokines/chemokines (IL‐1‐beta, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8/CXCL8, IL‐10, IL‐12p70, IL‐13, IL‐17A, GM‐CSF, TNF ...
Albert Aboseif +17 more
wiley +1 more source
When risks need attention: adoption of green supply chain initiatives in the pharmaceutical industry
International Journal of Production Research, 2018 The pharmaceutical industry is very important in delivering life-saving products/services to society. There are many ways for materials/products/services concerned with pharmaceuticals to influence the environment; these include improper disposal of ...
Anil Kumar +5 more
semanticscholar +1 more source
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin +10 more
wiley +1 more source
Molecules, 2018 ZL-004, a promising small molecule that increases white blood cell counts, was developed for extended-release nanosuspensions to improve low solubility and compliance of patients. In vivo pharmacokinetic studies of nanosuspensions with different particle
Chengyue Guo +6 more
doaj +1 more source
Innovation in the pharmaceutical industry [PDF]
BMJ, 1994 The pharmaceutical industry today is operating in an environment whose main feature is an unprecedented pace of change. In most markets the rising costs of health care are of increasing concern, and the medicines bill is being targeted for savings. New constraints are limiting the medicines that can be used and paid for in the system.
openaire +3 more sources
Heterogeneous batch distillation processes for waste solvent recovery in pharmaceutical industry [PDF]
, 2009 A summary about our experiences in the introduction of heterogeneous entrainers in azeotropic and extractive batch distillation is presented in this work.
Arias-Barreto, Alien +3 more
core +1 more source
JAMA Internal Medicine, 2018 This database analysis examines the extent to which pharmaceutical industry marketing of opioid products to physicians during 2014 was associated with opioid prescribing during 2015.
Scott E. Hadland +4 more
semanticscholar +1 more source